Oppenheimer Maintains Outperform on Sagimet Biosciences, Raises Price Target to $38

Oppenheimer analyst Jay Olson has maintained an 'Outperform' rating on Sagimet Biosciences (NASDAQ: SGMT) and increased the price target from $33 to $38.